|
1
|
Brown TA and McKnight SL: Specificities of
protein-protein and protein-DNA interaction of GABP alpha and two
newly defined ets-related proteins. Genes Dev. 6:2502–2512. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Haro L and Janknecht R: Functional
analysis of the transcription factor ER71 and its activation of the
matrix metalloproteinase-1 promoter. Nucleic Acids Res.
30:2972–2979. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hollenhorst PC, McIntosh LP and Graves BJ:
Genomic and biochemical insights into the specificity of ETS
transcription factors. Annu Rev Biochem. 80:437–471. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee D, Park C, Lee H, Lugus JJ, Kim SH,
Arentson E, Chung YS, Gomez G, Kyba M, Lin S, et al: ER71 acts
downstream of BMP, Notch, and Wnt signaling in blood and vessel
progenitor specification. Cell Stem Cell. 2:497–507. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferdous A, Caprioli A, Iacovino M, Martin
CM, Morris J, Richardson JA, Latif S, Hammer RE, Harvey RP, Olson
EN, et al: Nkx2-5 transactivates the Ets-related protein 71 gene
and specifies an endothelial/endocardial fate in the developing
embryo. Proc Natl Acad Sci USA. 106:pp. 814–819. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shalaby F, Rossant J, Yamaguchi TP,
Gertsenstein M, Wu XF, Breitman ML and Schuh AC: Failure of
blood-island formation and vasculogenesis in Flk-1-deficient mice.
Nature. 376:62–66. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park C, Lee TJ, Bhang SH, Liu F, Nakamura
R, Oladipupo SS, Pitha-Rowe I, Capoccia B, Choi HS, Kim TM, et al:
Injury-mediated vascular regeneration requires endothelial
ER71/ETV2. Arterioscler Thromb Vasc Biol. 36:86–96. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee D, Kim T and Lim DS: The Er71 is an
important regulator of hematopoietic stem cells in adult mice. Stem
Cells. 29:539–548. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Haro L and Janknecht R: Cloning of the
murine ER71 gene (Etsrp71) and initial characterization of its
promoter. Genomics. 85:493–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DiTacchio L, Bowles J, Shin S, Lim DS,
Koopman P and Janknecht R: Transcription factors ER71/ETV2 and SOX9
participate in a positive feedback loop in fetal and adult mouse
testis. J Biol Chem. 287:23657–23666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Otake T and Kuroiwa A: Molecular mechanism
of male differentiation is conserved in the SRY-absent mammal,
Tokudaia osimensis. Sci Rep. 6:328742016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim JY, Lee RH, Kim TM, Kim DW, Jeon YJ,
Huh SH, Oh SY, Kyba M, Kataoka H, Choi K, et al: OVOL2 is a
critical regulator of ER71/ETV2 in generating FLK1+,
hematopoietic, and endothelial cells from embryonic stem cells.
Blood. 124:2948–2952. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Knebel J, De Haro L and Janknecht R:
Repression of transcription by TSGA/Jmjd1a, a novel interaction
partner of the ETS protein ER71. J Cell Biochem. 99:319–329. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamane K, Toumazou C, Tsukada Y,
Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: JHDM2A, a
JmjC-containing H3K9 demethylase, facilitates transcription
activation by androgen receptor. Cell. 125:483–495. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kooistra SM and Helin K: Molecular
mechanisms and potential functions of histone demethylases. Nat Rev
Mol Cell Biol. 13:297–311. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson A, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mooney SM, Grande JP, Salisbury JL and
Janknecht R: Sumoylation of p68 and p72 RNA helicases affects
protein stability and transactivation potential. Biochemistry.
49:1–10. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dowdy SC, Mariani A and Janknecht R:
HER2/Neu- and TAK1-mediated up-regulation of the transforming
growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol
Chem. 278:44377–44384. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Janknecht R: Regulation of the ER81
transcription factor and its coactivators by mitogen- and
stress-activated protein kinase 1 (MSK1). Oncogene. 22:746–755.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim TD, Fuchs JR, Schwartz E, Abdelhamid
D, Etter J, Berry WL, Li C, Ihnat MA, Li PK and Janknecht R:
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon
cancer cells and identification of curcuminoids as JMJD2
inhibitors. Am J Transl Res. 6:236–247. 2014.PubMed/NCBI
|
|
21
|
Berry WL, Kim TD and Janknecht R:
Stimulation of β-catenin and colon cancer cell growth by the KDM4B
histone demethylase. Int J Oncol. 44:1341–1348. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Papoutsopoulou S and Janknecht R:
Phosphorylation of ETS transcription factor ER81 in a complex with
its coactivators CREB-binding protein and p300. Mol Cell Biol.
20:7300–7310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shin S, Kim TD, Jin F, van Deursen JM,
Dehm SM, Tindall DJ, Grande JP, Munz JM, Vasmatzis G and Janknecht
R: Induction of prostatic intraepithelial neoplasia and modulation
of androgen receptor by ETS variant 1/ETS-related protein 81.
Cancer Res. 69:8102–8110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oh S, Shin S, Lightfoot SA and Janknecht
R: 14-3-3 proteins modulate the ETS transcription factor ETV1 in
prostate cancer. Cancer Res. 73:5110–5119. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bosc DG, Goueli BS and Janknecht R:
HER2/Neu-mediated activation of the ETS transcription factor ER81
and its target gene MMP-1. Oncogene. 20:6215–6224. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shin S, Oh S, An S and Janknecht R: ETS
variant 1 regulates matrix metalloproteinase-7 transcription in
LNCaP prostate cancer cells. Oncol Rep. 29:306–314. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shin S and Janknecht R: Diversity within
the JMJD2 histone demethylase family. Biochem Biophys Res Commun.
353:973–977. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mooney SM, Goel A, D'Assoro AB, Salisbury
JL and Janknecht R: Pleiotropic effects of p300-mediated
acetylation on p68 and p72 RNA helicase. J Biol Chem.
285:30443–30452. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu J and Janknecht R: Regulation of the
ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1
and protein kinase A. J Biol Chem. 277:42669–42679. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goel A and Janknecht R: Concerted
activation of ETS protein ER81 by p160 coactivators, the
acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J
Biol Chem. 279:14909–14916. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beltran H, Prandi D, Mosquera JM, Benelli
M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV,
Varambally S, et al: Divergent clonal evolution of
castration-resistant neuroendocrine prostate cancer. Nat Med.
22:298–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cloos PA, Christensen J, Agger K, Maiolica
A, Rappsilber J, Antal T, Hansen KH and Helin K: The putative
oncogene GASC1 demethylates tri- and dimethylated lysine 9 on
histone H3. Nature. 442:307–311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim TD, Jin F, Shin S, Oh S, Lightfoot SA,
Grande JP, Johnson AJ, van Deursen JM, Wren JD and Janknecht R:
Histone demethylase JMJD2A drives prostate tumorigenesis through
transcription factor ETV1. J Clin Invest. 126:706–720. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim TD, Shin S and Janknecht R: ETS
transcription factor ERG cooperates with histone demethylase KDM4A.
Oncol Rep. 35:3679–3688. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim TD, Oh S, Lightfoot SA, Shin S, Wren
JD and Janknecht R: Upregulation of PSMD10 caused by the JMJD2A
histone demethylase. Int J Clin Exp Med. 9:10123–10134.
2016.PubMed/NCBI
|
|
36
|
Whetstine JR, Nottke A, Lan F, Huarte M,
Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M and Shi
Y: Reversal of histone lysine trimethylation by the JMJD2 family of
histone demethylases. Cell. 125:467–481. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Klose RJ, Yamane K, Bae Y, Zhang D,
Erdjument-Bromage H, Tempst P, Wong J and Zhang Y: The
transcriptional repressor JHDM3A demethylates trimethyl histone H3
lysine 9 and lysine 36. Nature. 442:312–316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Crawford HC, Fingleton B, Gustavson MD,
Kurpios N, Wagenaar RA, Hassell JA and Matrisian LM: The PEA3
subfamily of Ets transcription factors synergizes with
beta-catenin-LEF-1 to activate matrilysin transcription in
intestinal tumors. Mol Cell Biol. 21:1370–1383. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wei GH, Badis G, Berger MF, Kivioja T,
Palin K, Enge M, Bonke M, Jolma A, Varjosalo M, Gehrke AR, et al:
Genome-wide analysis of ETS-family DNA-binding in vitro and in
vivo. EMBO J. 29:2147–2160. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shin S and Janknecht R: Activation of
androgen receptor by histone demethylases JMJD2A and JMJD2D.
Biochem Biophys Res Commun. 359:742–746. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim TD, Shin S, Berry WL, Oh S and
Janknecht R: The JMJD2A demethylase regulates apoptosis and
proliferation in colon cancer cells. J Cell Biochem. 113:1368–1376.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim TD, Oh S, Shin S and Janknecht R:
Regulation of tumor suppressor p53 and HCT116 cell physiology by
histone demethylase JMJD2D/KDM4D. PLoS One. 7:e346182012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Katoh M and Katoh M: Identification and
characterization of JMJD2 family genes in silico. Int J Oncol.
24:1623–1628. 2004.PubMed/NCBI
|
|
44
|
Berry WL and Janknecht R: KDM4/JMJD2
histone demethylases: Epigenetic regulators in cancer cells. Cancer
Res. 73:2936–2942. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Labbe RM, Holowatyj A and Yang ZQ: Histone
lysine demethylase (KDM) subfamily 4: Structures, functions and
therapeutic potential. Am J Transl Res. 6:1–15. 2013.PubMed/NCBI
|
|
46
|
Hillringhaus L, Yue WW, Rose NR, Ng SS,
Gileadi C, Loenarz C, Bello SH, Bray JE, Schofield CJ and Oppermann
U: Structural and evolutionary basis for the dual substrate
selectivity of human KDM4 histone demethylase family. J Biol Chem.
286:41616–41625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Black JC, Van Rechem C and Whetstine JR:
Histone lysine methylation dynamics: Establishment, regulation, and
biological impact. Mol Cell. 48:491–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim J, Daniel J, Espejo A, Lake A, Krishna
M, Xia L, Zhang Y and Bedford MT: Tudor, MBT and chromo domains
gauge the degree of lysine methylation. EMBO Rep. 7:397–403.
2006.PubMed/NCBI
|
|
49
|
Huang Y, Fang J, Bedford MT, Zhang Y and
Xu RM: Recognition of histone H3 lysine-4 methylation by the double
tudor domain of JMJD2A. Science. 312:748–751. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hadler-Olsen E, Winberg JO and
Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as
diagnostic and prognostic markers and therapeutic targets. Tumour
Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shay G, Lynch CC and Fingleton B: Moving
targets: Emerging roles for MMPs in cancer progression and
metastasis. Matrix Biol 44–46. 1–206. 2015.
|
|
52
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Patani N, Jiang WG, Newbold RF and Mokbel
K: Histone-modifier gene expression profiles are associated with
pathological and clinical outcomes in human breast cancer.
Anticancer Res. 31:4115–4125. 2011.PubMed/NCBI
|
|
54
|
Slee RB, Steiner CM, Herbert BS, Vance GH,
Hickey RJ, Schwarz T, Christan S, Radovich M, Schneider BP,
Schindelhauer D and Grimes BR: Cancer-associated alteration of
pericentromeric heterochromatin may contribute to chromosome
instability. Oncogene. 31:3244–3253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Berry WL, Shin S, Lightfoot SA and
Janknecht R: Oncogenic features of the JMJD2A histone demethylase
in breast cancer. Int J Oncol. 41:1701–1706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li LL, Xue AM, Li BX, Shen YW, Li YH, Luo
CL, Zhang MC, Jiang JQ, Xu ZD, Xie JH and Zhao ZQ: JMJD2A
contributes to breast cancer progression through transcriptional
repression of the tumor suppressor ARHI. Breast Cancer Res.
16:R562014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mallette FA and Richard S: JMJD2A promotes
cellular transformation by blocking cellular senescence through
transcriptional repression of the tumor suppressor CHD5. Cell Rep.
2:1233–1243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Xu W, Jiang K, Shen M, Qian Y and Peng Y:
SIRT2 suppresses non-small cell lung cancer growth by targeting
JMJD2A. Biol Chem. 396:929–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xu CX, Lee TJ, Sakurai N, Krchma K, Liu F,
Li D, Wang T and Choi K: ETV2/ER71 regulates hematopoietic
regeneration by promoting hematopoietic stem cell proliferation. J
Exp Med. 214:1643–1653. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pedersen MT, Kooistra SM, Radzisheuskaya
A, Laugesen A, Johansen JV, Hayward DG, Nilsson J, Agger K and
Helin K: Continual removal of H3K9 promoter methylation by Jmjd2
demethylases is vital for ESC self-renewal and early development.
EMBO J. 35:1550–1564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ginsberg M, James D, Ding BS, Nolan D,
Geng F, Butler JM, Schachterle W, Pulijaal VR, Mathew S, Chasen ST,
et al: Efficient direct reprogramming of mature amniotic cells into
endothelial cells by ETS factors and TGFβ suppression. Cell.
151:559–575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Han JK, Chang SH, Cho HJ, Choi SB, Ahn HS,
Lee J, Jeong H, Youn SW, Lee HJ, Kwon YW, et al: Direct conversion
of adult skin fibroblasts to endothelial cells by defined factors.
Circulation. 130:1168–1178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ginsberg M, Schachterle W, Shido K and
Rafii S: Direct conversion of human amniotic cells into endothelial
cells without transitioning through a pluripotent state. Nat
Protoc. 10:1975–1985. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wong WT and Cooke JP: Therapeutic
transdifferentiation of human fibroblasts into endothelial cells
using forced expression of lineage-specific transcription factors.
J Tissue Eng. 7:2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Morita R, Suzuki M, Kasahara H, Shimizu N,
Shichita T, Sekiya T, Kimura A, Sasaki K, Yasukawa H and Yoshimura
A: ETS transcription factor ETV2 directly converts human
fibroblasts into functional endothelial cells. Proc Natl Acad Sci
USA. 112:pp. 160–165. 2015; View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Van Pham P, Vu NB, Nguyen HT, Huynh OT and
Truong MT: Significant improvement of direct reprogramming efficacy
of fibroblasts into progenitor endothelial cells by ETV2 and
hypoxia. Stem Cell Res Ther. 7:1042016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lee S, Park C, Han JW, Kim JY, Cho K, Kim
EJ, Kim S, Lee SJ, Oh SY, Tanaka Y, et al: Direct reprogramming of
human dermal fibroblasts into endothelial cells using ER71/ETV2.
Circ Res. 120:848–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Iwamori N, Zhao M, Meistrich ML and Matzuk
MM: The testis-enriched histone demethylase, KDM4D, regulates
methylation of histone H3 lysine 9 during spermatogenesis in the
mouse but is dispensable for fertility. Biol Reprod. 84:1225–1234.
2011. View Article : Google Scholar : PubMed/NCBI
|
